Literature DB >> 35132596

Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.

Ritwik Patra1, Nabarun Chandra Das1, Suprabhat Mukherjee2.   

Abstract

INTRODUCTION: Coronavirus disease-19 (COVID-19) caused by SARS-CoV-2 is presently the biggest threat to mankind throughout the globe. Increasing reports on deaths, cases of new infection, and socioeconomic losses are continuously coming from all parts of the world. Developing an efficacious drug and/or vaccine is currently the major goal to the scientific communities. In this context, toll-like receptors (TLRs) could be the useful targets in adopting effective therapeutic approaches.
METHODS: This chapter has been written by incorporating the findings on TLR-based therapies against SARS-CoV-2 demonstrated in the recently published research papers/reviews.
RESULTS: TLRs are the essential components of host immunity and play critical roles in deciding the fate of SARS-CoV-2 by influencing the immunoregulatory circuits governing human immune response to this pathogen. Hitherto, a number of multi-subunit peptide-based vaccines and pharmacological agents developed against SARS-CoV-2 have been found to manipulate TLR function. Therefore, circumventing overt immunopathology of COVID-19 applying TLR-antagonists can effectively reduce the morality caused from "cytokine storm"-induced multiorgan failure. Similarly, pre-administration of TLR- agonists may be used as a prophylaxis to sensitize the immune system of the individuals having risk of infection. A lot of collaborative efforts are required for bench-to-bench transformation of these knowledges.
CONCLUSION: This chapter enlightens the potentials and promises of TLR-guided therapeutic strategies against COVID-19 by reviewing the major findings and achievements depicted in the literatures published till date.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  COVID-19; Immunity; Immunotherapeutic intervention; SARS-CoV-2; Toll-like receptors; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 35132596     DOI: 10.1007/978-3-030-85109-5_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  87 in total

Review 1.  Toll-like receptors: promising therapeutic targets for inflammatory diseases.

Authors:  Asma Achek; Dhanusha Yesudhas; Sangdun Choi
Journal:  Arch Pharm Res       Date:  2016-08-11       Impact factor: 4.946

2.  COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.

Authors:  Cornelia C Bergmann; Robert H Silverman
Journal:  Cleve Clin J Med       Date:  2020-05-04       Impact factor: 2.321

Review 3.  Cross-talk between pro-inflammatory transcription factors and glucocorticoids.

Authors:  I M Adcock; G Caramori
Journal:  Immunol Cell Biol       Date:  2001-08       Impact factor: 5.126

4.  Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future.

Authors:  Chris T Bauch; James O Lloyd-Smith; Megan P Coffee; Alison P Galvani
Journal:  Epidemiology       Date:  2005-11       Impact factor: 4.822

Review 5.  Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets.

Authors:  Fatih Arslan; Dominique P V de Kleijn; Leo Timmers; Pieter A Doevendans; Gerard Pasterkamp
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.

Authors:  Mazin Barry; Curtis Cooper
Journal:  Expert Opin Biol Ther       Date:  2007-11       Impact factor: 4.388

Review 7.  Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

Authors:  Ulf Andersson; William Ottestad; Kevin J Tracey
Journal:  Mol Med       Date:  2020-05-07       Impact factor: 6.354

8.  Assessing the pandemic potential of MERS-CoV.

Authors:  Chris T Bauch; Tamer Oraby
Journal:  Lancet       Date:  2013-07-05       Impact factor: 79.321

9.  Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach.

Authors:  Miyssa I Abdelmageed; Abdelrahman H Abdelmoneim; Mujahed I Mustafa; Nafisa M Elfadol; Naseem S Murshed; Shaza W Shantier; Abdelrafie M Makhawi
Journal:  Biomed Res Int       Date:  2020-05-11       Impact factor: 3.411

10.  The proximal origin of SARS-CoV-2.

Authors:  Kristian G Andersen; Andrew Rambaut; W Ian Lipkin; Edward C Holmes; Robert F Garry
Journal:  Nat Med       Date:  2020-04       Impact factor: 87.241

View more
  2 in total

Review 1.  Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.

Authors:  Yujie Jiang; Tingmei Zhao; Xueyan Zhou; Yu Xiang; Pedro Gutierrez-Castrellon; Xuelei Ma
Journal:  MedComm (2020)       Date:  2022-08-01

Review 2.  Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments.

Authors:  Zhi-Mei Liu; Ming-Hui Yang; Kun Yu; Zheng-Xing Lian; Shou-Long Deng
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.